Evaluating XPO1 Inhibitors in Multiple Myeloma and their Potential Role in Myelofibrosis

home / precision-medicine / evaluating-xpo1-inhibitors-in-multiple-myeloma-and-their-potential-role-in-myelofibrosis

Expert hematologist-oncologists share insight on the evolving role of XPO1 inhibitor therapy in the management of multiple myeloma and myelofibrosis.

Overview of Relapsed/Refractory Multiple Myeloma

EP. 1: Overview of Relapsed/Refractory Multiple Myeloma

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Joshua Richter, MD, gives an overview of relapse/refractory multiple myeloma and the available treatment options.

Watch

Mechanism of Action of Selinexor and its Role in Multiple Myeloma

EP. 2: Mechanism of Action of Selinexor and its Role in Multiple Myeloma

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Dr Joshua Richter describes the mechanism of action of XPO1 inhibitor selinexor and its use in treating multiple myeloma.

Watch

Selinexor in Multiple Myeloma: Review of Clinical Trial Data

EP. 3: Selinexor in Multiple Myeloma: Review of Clinical Trial Data

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Joshua Richter, MD, reviews data from two clinical trials investigating selinexor combination therapies for the treatment of multiple myeloma.

Watch

Overview of Triple Class Refractory Multiple Myeloma

EP. 4: Overview of Triple Class Refractory Multiple Myeloma

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Dr Joshua Richter explains triple class refractory myeloma and the need for more data on treatment options.

Watch

Updates on Selinexor Triplet Combination Therapies from ASH 2022

EP. 5: Updates on Selinexor Triplet Combination Therapies from ASH 2022

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Joshua Richter, MD, highlights key data from an update to a study investigating a selinexor triplet combination therapy.

Watch

Determining Which Patients With Multiple Myeloma are Candidates for Triplet Combination Therapies

EP. 6: Determining Which Patients With Multiple Myeloma are Candidates for Triplet Combination Therapies

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Dr Joshua Richter explains which patients with multiple myeloma are most suitable for triplet combination therapies.

Watch

Defining Myelofibrosis and Identifying Clinical Symptoms

EP. 7: Defining Myelofibrosis and Identifying Clinical Symptoms

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Srdan Verstovsek, MD, provides an overview of myelofibrosis and the clinical signs and symptoms to look for.

Watch

The JAK-STAT Pathway in the Treatment of Myelofibrosis

EP. 8: The JAK-STAT Pathway in the Treatment of Myelofibrosis

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Dr Srdan Verstovsek, MD, details how the JAK-STAT pathway is utilized in the treatment of myelofibrosis.

Watch

Combination Ruxolitinib and Selinexor for the Treatment of Naïve Myelofibrosis

EP. 9: Combination Ruxolitinib and Selinexor for the Treatment of Naïve Myelofibrosis

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination ruxolitinib and selinexor for the frontline treatment of myelofibrosis.

Watch

The Role of Ruxolitinib in Myelofibrosis Treatment

EP. 10: The Role of Ruxolitinib in Myelofibrosis Treatment

Joshua Richter, MD;Srdan Verstovsek, MD, PhD
January 30th 2023

Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.

Watch